Cargando…

The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis

BACKGROUND: Studies on the prognostic value of the soluble programmed death ligand 1 (sPD-L1) in cancer patients have not yielded consistent results. OBJECTIVE: This meta-analysis was performed to assess the association between sPD-L1 and the prognosis of cancer patients. METHODS: Published articles...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Pei, Hu, Wei, Zhu, Ying, Wu, Yushen, Lin, Huapeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7950317/ https://www.ncbi.nlm.nih.gov/pubmed/33718120 http://dx.doi.org/10.3389/fonc.2020.626932

Ejemplares similares

Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Liao, Guixiang, et al.
Publicado: (2021)

Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis
por: Huang, Yilong, et al.
Publicado: (2020)

Prognostic Value of Galectin-9 Relates to Programmed Death-Ligand 1 in Patients With Multiple Myeloma
por: Lee, Byung-Hyun, et al.
Publicado: (2021)

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients
por: Liu, Xiaofeng, et al.
Publicado: (2019)

The predictive role of soluble programmed death ligand 1 in digestive system cancers
por: Ruan, Jian, et al.
Publicado: (2023)

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort With Clear Cell Renal Cell Carcinoma
por: Xiao, Wen-jun, et al.
Publicado: (2019)

Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: A meta-analysis
por: Wei, Wei, et al.
Publicado: (2018)

Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis
por: Cai, Huarong, et al.
Publicado: (2020)

Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis
por: Zhang, Chen, et al.
Publicado: (2021)

The Clinical Significance of Soluble Programmed Cell Death-Ligand 1 (sPD-L1) in Patients With Gliomas
por: Liu, Shujun, et al.
Publicado: (2020)

The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer
por: Shao, Weifang, et al.
Publicado: (2022)

Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis
por: Zhu, Zhenhua, et al.
Publicado: (2017)

Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients
por: Wang, Feng, et al.
Publicado: (2020)

The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
por: Chang, Boyang, et al.
Publicado: (2018)

The Efficacy and Safety of Programmed Death-1 and Programmed Death Ligand 1 Inhibitors for the Treatment of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: He, Shukang, et al.
Publicado: (2021)

Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis
por: Guo, Yawen, et al.
Publicado: (2016)

Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
por: Park, Woochan, et al.
Publicado: (2021)

Prognostic Function of Programmed Cell Death-Ligand 1 in Esophageal Squamous Cell Carcinoma Patients Without Preoperative Therapy: A Systematic Review and Meta-Analysis
por: Cui, Hongxia, et al.
Publicado: (2021)

Prognostic and predictive role of soluble programmed death ligand-1 in head and neck cancer
por: Molga-Magusiak, Maria, et al.
Publicado: (2023)

Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers
por: Liang, Sheng-Kai, et al.
Publicado: (2021)

The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures
por: Shi, Tao, et al.
Publicado: (2021)

The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis
por: Zhao, Shu, et al.
Publicado: (2018)

Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
por: Piao, Jinlan, et al.
Publicado: (2020)

Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis
por: Zhang, Yingzi, et al.
Publicado: (2020)

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials
por: Li, Zaishang, et al.
Publicado: (2021)

Prognostic value of epithelial–mesenchymal transition circulating tumor cells in female breast cancer: A meta-analysis
por: Zhao, Qiang, et al.
Publicado: (2022)

Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
por: Iafolla, Marco A. J., et al.
Publicado: (2017)

Soluble Programmed Death Receptor Ligands sPD-L1 and sPD-L2 as Liquid Biopsy Markers for Prognosis and Platinum Response in Epithelial Ovarian Cancer
por: Buderath, Paul, et al.
Publicado: (2019)

Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma
por: Pal, Krishnendu, et al.
Publicado: (2022)

Correlation Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Programmed Death-Ligand 1 Expression as Prognostic Markers in Non-Small Cell Lung Cancer
por: Pirlog, Cristina-Florina, et al.
Publicado: (2022)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
por: Banerjee, Debasree, et al.
Publicado: (2018)

Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
por: Xian, Feng, et al.
Publicado: (2023)

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
por: Klotz, Daniel Martin, et al.
Publicado: (2022)

Prognostic value and immune infiltration of the gasdermin family in lung adenocarcinoma
por: Peng, Lu-Shan, et al.
Publicado: (2022)

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors
por: Song, Joon Seon, et al.
Publicado: (2019)

Prognostic Role of Programmed Death Ligand-1 on Tumor-Infiltrating Immune Cells in “High-Risk” Patients Following Radical Cystectomy: A Retrospective Cohort Study
por: Lee, Chung Un, et al.
Publicado: (2021)

A Machine Learning-Based Model to Predict Survival After Transarterial Chemoembolization for BCLC Stage B Hepatocellular Carcinoma
por: Lin, Huapeng, et al.
Publicado: (2021)

Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes
por: Liao, Haotian, et al.
Publicado: (2019)

The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer
por: Zhao, Rongling, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3vst2rbpnfkq1jjv9fql168h8f